Funding Opportunity RFA-CA-22-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Funding Opportunity RFA-CA-22-011 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in United States (U.S.) and investigators in LMICs. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. These partnerships are referred to as HIV-Associated Malignancy Research Centers (HAMRCs). Each proposed U54 HAMRC should be based upon partnerships involving at least one U.S. institution and institutions from at least two or more LMICs. Each HAMRC application is required to propose between two to three research projects that address questions in one scientific theme (e.g. viral-associated cancers) that is relevant to HIV-associated malignancies in LMICs or the U.S. The proposed projects may range, as appropriate, from basic research to translational efforts as well as to population and implementation studies. Mechanistic clinical studies that meet NIH's definition of a clinical trial will be allowed. In addition, the proposed U54 HAMRC must include an Administrative Core and a Developmental Core.

Funding Opportunity RFA-DA-22-048 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage pilot and preliminary research in preparation for larger-scale services research effectiveness trials focused on personalized treatment and prevention services approaches to address polysubstance use. Research of interest includes, but is not limited to, developmental work toward future full-scale clinical trials to study service delivery and personalized, tailored treatment approaches, including understanding implementation approaches to support delivery of complex service bundles.

Funding Opportunity RFA-DA-22-047 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support R01-level projects that will 1) expand the understanding of the dynamics of polysubstance use, 2) examine service provision in the context of polysubstance use, exploring the impacts of existing policies and services on treatment outcomes for individuals who use multiple substances and have one or more substance use disorders, and 3) study personalized treatment and services approaches to address polysubstance use.

Funding Opportunity RFA-DA-22-043 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for infrastructure support to advance the development of efficacy and/or effectiveness research on recovery support services for those take or have taken medications for the treatment of opioid use disorder (MOUDs). The infrastructure support will facilitate multi-stakeholder (e.g. researchers and students, payors, providers, persons in recovery) research networks through meetings, conferences, small-scale pilots, data development work, short-term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and to build resources for advancing recovery support services research. Network applications are to support research related to the following priority recovery support services research areas include active recovery communities, recovery residences, education-based recovery support services, continuing care models, recovery support services to meet the needs of specific minority health populations, recovery support services to meet the needs of specific health disparities populations, recovery support services provided in regions of the United States not covered by existing Recovery Research Network projects, or others proposed by applicants.

Funding Opportunity RFA-DA-22-042 from the NIH Guide for Grants and Contracts. This FOA seeks applications for a single coordination center for the Harm Reduction Network. Key activities for the Coordination Center would include (1) providing logistical and coordination support for the network; (2) providing data harmonization and data sharing supports; (3) convening key stakeholders, (4) developing research and clinical practice resources, including facilitating the development of common metrics defining effective harm reduction, with input from the network, conducting landscape analyses and other research to determine the evolution of harm reduction practices nationally, and developing translational products and tools based on findings from studies funded under this initiative. This FOA runs in parallel with a companion FOA that seeks applications to develop evidence-based harm reduction strategies.

Funding Opportunity RFA-DA-22-046 from the NIH Guide for Grants and Contracts. This funding opportunity announcement seeks R01-level projects aimed at increasing our understanding of the effectiveness, implementation, and impact of existing and new harm reduction practices to address the ongoing opioid crisis and substance use disorder more broadly. Projects may include: (1) developing and testing new harm reduction strategies; (2) examining how to effectively implement new and existing harm reduction strategies; (3) expanding the settings and delivery models through which harm reduction strategies are deployed; and (4) examining the impact of new harm reduction policies implemented at state and local levels.

Funding Opportunity RFA-DA-22-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research to prepare for rigorous clinical efficacy or effectiveness trials of recovery support services for individuals who take or have taken medications for opioid use disorder (MOUDs). Relevant trials may test a wide range of services where rigorous evidence of efficacy and effectiveness are needed including peer-based recovery support, recovery community centers, active recovery communities, recovery residences, education-based recovery support services, continuing care models, recovery support services to meet the needs of specific minority health populations, recovery support services to meet the needs of specific health disparities populations, combinations of these recovery support services, or others proposed by applicants.

Notice NOT-HD-21-053 from the NIH Guide for Grants and Contracts

Notice NOT-MD-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-AR-22-012 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-063 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-065 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-034 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-053 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-009 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA)is to support research addressing critical knowledge gaps in our understanding of how lipids contribute to vulnerability and resilience to brain aging and Alzheimers disease (AD)and its related dementias (ADRD), including research addressing how: 1) lipid droplets affect brain aging and AD, including whether their accumulation is pathological or protective; (2) the periphery interacts with lipids in the aging brain, including whether these could be targets for future biomarkers; (3) APOE and lipid-mediated signaling influence brain aging and AD/ADRD progression; and (4) myelin lipids and their signaling contribute to brain aging and AD/ADRD.

Notice NOT-AG-21-033 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-050 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-047 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-046 from the NIH Guide for Grants and Contracts